Alternative strategies

Carmignac Portfolio Merger Arbitrage Plus

Share Class

LU2585801330

Carmignac Portfolio Merger Arbitrage Plus fund performance

Performance Overview

Data as of:  1 Jun 2025.

Calendar Year Performance (as %)

Calendar Year Performance (as %)

Data as of:  30 Apr 2025.
Carmignac Portfolio Merger Arbitrage Plus - I EUR Acc
Carmignac Portfolio Merger Arbitrage Plus I EUR Acc+1.7 %+0.7 %+1.4 %+5.0 %---
Category Average-------
Ranking (quartile)-------
​Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor). Morningstar Rating™ :  © Morningstar, Inc. All Rights Reserved. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
Source: Carmignac at 30/04/2025.

Statistics (%)

These measures are used to assess a Fund's risk-adjusted performance. A well-performing Fund should ideally have a solid return (measured by the Sharpe ratio and alpha) relative to its risk (measured by volatility), while being well aligned with market expectations (measured by beta relative to the reference indicator).

Volatility

Data as of:  30 Apr 2025.
Fund+2.1 %-+2.0 %

Calculation : Weekly basis

Ratio

Data as of:  30 Apr 2025.
Sharpe Ratio +0.8 %-+0.3 %
Beta0.0 %-0.0 %
Alpha0.0 %-0.0 %

Calculation : Weekly basis

Source: Carmignac at 30 Apr 2025.

Comments from the Investment Team

Read the Investment team's analysis below.

Carmignac Portfolio Merger Arbitrage Plus Monthly comments

Data as of:  30 Apr 2025.
The Investment team

Market Environment

• Following on from March, April was a challenging month to manage. Most asset classes ended slightly down in a highly volatile environment. Against this backdrop, the merger arbitrage strategy once again demonstrated its resilience. The HFRX Merger Arbitrage Index posted a positive monthly performance of +0.51% (in dollar terms).• However, some spreads proved slightly more volatile than average. This was particularly true of the acquisition of Spirent Communications by US company VIavi Solution, which is still awaiting approval from the Chinese antitrust authorities. • Although China has stated that it will continue its review process as planned, the market fears opposition due to recent political tensions. These same fears are affecting the Ansys/Synopsis deal. In addition, deals currently being challenged by the US authorities, such as Surmodics, have also been more volatile in the uncertain market environment. • Despite the uncertain economic and political environment, it is important to note that there has been some bidding wars. We benefited from the improved offer from private equity firm HIG Capital for Converge Technology following interest from a third party, as well as the improved price offered by Equinox Gold for Calibre Mining. • Around 20 transactions were completed, which contributed to the narrowing of all other spreads. • Uncertainties related to the trade war launched by the Trump administration slowed M&A activity in the United States in particular. Only 13 transactions were announced, including eight in Europe and one in Asia. • We also believe it is important to highlight possible regulatory changes in the United States with the proposed ‘One Agency Act’. This bill aims to consolidate the power to enforce federal antitrust laws within the Department of Justice (DOJ), which could potentially affect companies involved in mergers and acquisitions (M&A) or under investigation or litigation by the Federal Trade Commission (FTC). • Supporters of this bill argue that dual oversight by the FTC and the DOJ is redundant and inefficient. The One Agency Act would transfer antitrust enforcement authority solely to the DOJ, eliminating the FTC's ability to bring actions under Section 5 of the FTC Act, which deals with ‘unfair methods of competition’. • This could reduce the scope of anti-competitive behaviour that can be prosecuted by the federal government. This is a proposed bill, and there are significant obstacles to its implementation.

Performance Commentary

• The fund posted a positive performance during the month.• Main positive contributors to performance were: Calibre Mining, Converge Technology, Discover Financial and ChampionX. • Main detractors to performance were: Surmodics, Spirent and Ansys.

Outlook and Investment Strategy

• The fund's investment ratio is 102%, up from the previous month.• With 45 positions in the portfolio, diversification remains satisfactory. • 2025 continues to look much more promising than 2024 thanks to a more favourable antitrust environment for M&A activity worldwide: the change of administration in the US following Trump's election, the publication of the Draghi report in Europe recommending the emergence of national champions to face global competition, regulators in the UK being pushed by politicians to prioritise economic activity, and the Japanese market continuing to open up to foreign capital. • Lower interest rates should also drive M&A activity in the coming quarters. • However, instability linked to the trade war launched by the Trump administration and geopolitical tensions are slowing the recovery, which is less robust than we had hoped.

Related articles

Alternative Strategy14 April 2025English

Carmignac Portfolio Merger Arbitrage Plus: Letter from the Fund Managers

3 minute(s) read
Find out more
Alternative Strategy17 January 2025English

Carmignac Portfolio Merger Arbitrage Plus: Letter from the Fund Managers

2 minute(s) read
Find out more
Alternative Strategy9 October 2024English

Carmignac Portfolio Merger Arbitrage Plus: Letter from the Fund Managers

4 minute(s) read
Find out more
Reference to certain securities and financial instruments is for illustrative purposes to highlight stocks that are or have been included in the portfolios of funds in the Carmignac range. This is not intended to promote direct investment in those instruments, nor does it constitute investment advice. The Management Company is not subject to prohibition on trading in these instruments prior to issuing any communication. The portfolios of Carmignac funds may change without previous notice.
The reference to a ranking or prize, is no guarantee of the future results of the UCIS or the manager.
Carmignac Portfolio is a sub-fund of Carmignac Portfolio SICAV, an investment company under Luxembourg law, conforming to the UCITS Directive.
The information presented above is not contractually binding and does not constitute investment advice. Past performance is not a reliable indicator of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor), where applicable. Investors may lose some or all of their capital, as the capital in the UCI is not guaranteed. Access to the products and services presented herein may be restricted for some individuals or countries. Taxation depends on the situation of the individual. The risks, fees and recommended investment period for the UCI presented are detailed in the KIDs (key information documents) and prospectuses available on this website. The KID must be made available to the subscriber prior to purchase.). The reference to a ranking or prize, is no guarantee of the future results of the UCITS or the manager.